{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:37:35Z","timestamp":1783489055103,"version":"3.55.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Extramammary Paget disease (EMPD) is a rare epithelial adenocarcinoma in apocrine-gland rich skin, involving the vulva, the scrotum, and the penis. with distant metastases and a poor prognosis. Local EMPD patients generally have a good prognosis, with expected 5-year survival of 60%\u201392%, but distant metastasis represents poor prognosis and 5-year survival of 10%. Treatment approaches for advanced EMPD are chemotherapy and biological agents, which carry limited efficacy. We report the case of a 57-year-old man diagnosed with metastatic EMPD, who showed a long-term disease control with a combination therapy (an immune checkpoint inhibitor - tislelizumab plus chemotherapy \u2013 paclitaxel albumin and cisplatin). This patient underwent a wide penile scrotal lesion excision and six cycles of tislelizumab plus chemotherapy. The patient achieved partial response for the metastatic lesions according to the Response Evaluation Criteria in Solid Tumors (version 1.1). This case report supports further investigation of the combination treatment of chemotherapy and immune checkpoint inhibitors in the management of metastatic EMPD, which currently has an abysmal prognosis and no standardized treatment.<\/jats:p>","DOI":"10.3389\/fonc.2024.1402490","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:10:22Z","timestamp":1729743022000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Tislelizumab plus chemotherapy in metastatic extramammary Paget disease after surgery: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Dongxing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000002064","article-title":"Extramammary paget disease: A review of the literature\u2014Part I: history, epidemiology, pathogenesis, presentation, histopathology, and diagnostic work-up","volume":"46","author":"Morris","year":"2020","journal-title":"Dermatologic Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2022.08.001","article-title":"Extramammary Paget\u2019s disease: Updates in the workup and management","volume":"9","author":"Nabavizadeh","year":"2022","journal-title":"Asian J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15285","article-title":"Outcomes of lymph node dissection in the treatment of extramammary Paget\u2019s disease: A single-institution study","volume":"47","author":"Tsutsui","year":"2020","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00038","article-title":"Metastatic extramammary paget\u2019s disease: pathogenesis and novel therapeutic approach","volume":"8","author":"Fukuda","year":"2018","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.06.004","article-title":"A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors","volume":"83","author":"Ohara","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000506832","article-title":"Nonsurgical treatments for extramammary paget disease: A systematic review and meta-analysis","volume":"236","author":"Snast","year":"2020","journal-title":"Dermatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14247","article-title":"Efficacy of low-dose 5-fluorouracil\/cisplatin therapy for invasive extramammary Paget\u2019s disease","volume":"45","author":"Kato","year":"2018","journal-title":"J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-014-0686-2","article-title":"Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget\u2019s disease","volume":"20","author":"Tokuda","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13200","article-title":"Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget\u2019s disease","volume":"43","author":"Yoshino","year":"2016","journal-title":"J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28040260","article-title":"Extramammary paget\u2019s disease: diagnosis, pathogenesis, and treatment with focus on recent developments","volume":"28","author":"Ishizuki","year":"2021","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000514345","article-title":"Treatment of metastatic extramammary paget disease with combination ipilimumab and nivolumab: A case report","volume":"14","author":"Guercio","year":"2021","journal-title":"Case Rep Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.891958","article-title":"Treatment of metastatic primary extramammary paget disease with combination anlotinib and tislelizumab: A case report and review of the literature","volume":"9","author":"Yin","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0214","article-title":"Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application","volume":"6","author":"Tray","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1402490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:10:24Z","timestamp":1729743024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1402490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":14,"alternative-id":["10.3389\/fonc.2024.1402490"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1402490","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"article-number":"1402490"}}